Source: Cancer Network, June 2025
The addition of relatlimab (Opdualag) to nivolumab (Opdivo) exhibited comparable efficacy outcomes vs ipilimumab (Yervoy) and nivolumab in patients with advanced melanoma, according to an updated 4-year indirect treatment comparison (ITC) analysis between the phase 2/3 RELATIVITY-047 trial (NCT03470922) and the phase 3 CheckMate-067 trial (NCT01844505) presented in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Efficacy results from the analysis revealed that after balancing key baseline characteristics for the nivolumab/relatlimab (n = 339) and nivolumab/ipilimumab groups (n = 297), investigator-assessed progression-free survival (PFS; HR, 1.08; 95% CI, 0.89-1.33) and overall survival (OS; HR, 0.95; 95% CI, 0.76-1.19) outcomes after weighting were similar between both groups. The median PFS in each arm, respectively, was 12.0 months (95% CI, 8.2-17.1) vs 11.2 months (95% CI, 8.5-18.1). Additionally, the median OS was 64.5 months (95% CI, 38.6-not reached [NR]) with relatlimab vs NR (95% CI, 37.1-NR) with ipilimumab.